INDUSTRY NEWS

00.003-HB-Feb-2022

Global real-world evidence (RWE) market is expected to grow at a CAGR of 11.8% to 2028 to reach $4.4 billion

  • There is a rise in the dependence of outcome-based studies on real-world data, increasing the need for additional insights of clinical trials or medical research
  • Increasing investment by pharmaceutical companies and demand for RWD & RWE are the key drivers behind this growth trend
  • The growing burden of chronic disease is the big factor behind increasing demand of RWE to get more insights in order to develop an effective drug, treatment or a medical device
  • In the healthcare industry there is a huge amount of data which is generated on a daily basis with the help of digital devices that we all are using, which is analysed through RWE to achieve the targets of medical research
  • This study also discusses some of the key challenges faced by researchers while using RWD, key players of RWE market and which countries are contributing more to the rapid growth of RWE

 

Click here to learn more.

About SVMPharma

SVMPharma is an innovative strategic consultancy, specialising in Real-World Evidence (RWE) for the pharmaceutical industry. SVMPharma generates RWE within UK and Europe through bespoke online Real-World Treatment Evaluators, leading to successful health technology appraisal (HTA) submissions. Clinical trial programmes do not reflect real-world clinical practice and outcomes, RWE supplements and enhances clinical datasets. SVMPharma’s specialist teams focus on delivering the outcomes that matter to your brand.

For more information, please visit www.svmpharma.com and contact us at enquiry@svmpharma.com

ref: FEB2022HB003